Arrayjet Launches Outsourced Microarray Service
News Apr 22, 2016
Arrayjet has launched a pioneering in-house consultancy service designed to meet the needs of research laboratories across the globe requiring an outsourced fully time-scaled microarray printing facility. Called Arrayjet Advance™, the initiative has been developed to offer life science companies and research labs a dedicated microarray analytical results service by providing access to Arrayjet’s in-house scientific team and fully automated laboratory complex.
The service will produce fast, reproducible and precision-accurate microarray analytics through Arrayjet’s novel inkjet technology and instrumentation processes for a broad spectrum of diagnostic applications.
Dr Iain McWilliam, Chief Executive Officer, Arrayjet's comments, ''We understand that the life sciences and healthcare industries need high-end, high quality, fast paced research and that microarrays are one of the key tools used to get accurate results. We believe by developing our strategy to become a complete solutions provider through the creation of Arrayjet Advance, we are better placed to help our customers achieve good quality data on which to make decisions, by either providing an instrument, printed slides or a full microarray service with data analysis.
“We are seeing an increasing number of research laboratories looking to adopt microarray technology and as Arrayjet has accumulated considerable experience in helping purchasers of our instrumentation technology to prepare microarrays, this trend provided us with an opportunity to start an unrivalled outsourced contract service for printing microarrays to customer specifications. I believe this to be a great value-add service for the broader life sciences industry.”
Arrayjet’s microarray technology prints high-density arrays of microscopic spots of biological solutions on to solid substrates that can be used as diagnostic devices for healthcare and high-throughput screening tools for the life sciences diagnostics market, where it supports a variety of genomic, proteomic and glycomic applications.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018